Prevnar 13 by Pfizer Inc. - pneumococcal vaccine quietly powering a key franchise

Prevnar 13 protects against 13 pneumococcal serotypes and remains a core vaccine in Pfizer’s portfolio. This product is driving the price of Pfizer Inc. stock (ISIN US7170811035).

Prevnar 13 sits in a steel tray next to a row of syringes, its clear liquid catching the cold light of the clinic fridge as pediatrician Dr. Elena Ruiz checks another child’s vaccination record before a routine shot.

Conjugate vaccine for 13 serotypes

Prevnar 13 is Pfizer’s pneumococcal conjugate vaccine designed to protect against 13 common serotypes of Streptococcus pneumoniae, including 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. The vaccine links polysaccharide antigens from these serotypes to a carrier protein to trigger a robust T?cell dependent immune response, particularly in young children whose immune systems respond poorly to plain polysaccharide vaccines. In practice, this means Prevnar 13 can help prevent invasive pneumococcal disease such as bacterial meningitis, sepsis and bacteremic pneumonia, along with certain cases of otitis media caused by the covered serotypes.

Pfizer developed Prevnar 13 as the successor to its earlier 7?valent conjugate vaccine, adding six more serotypes including 19A, which had become notable for antibiotic resistance and disease burden in multiple regions. The product received its first regulatory approvals in 2009 and 2010, including from the US Food and Drug Administration and the European Medicines Agency, initially for infants and young children. Over time, indications expanded to include older children and adults over 50, reflecting evidence that conjugate vaccination could reduce both invasive disease and certain forms of non?bacteremic pneumonia in older age groups. Pfizer’s vaccine portfolio head, Dr. Kathrin Jansen, has frequently pointed to Prevnar 13 as a cornerstone in the company’s strategy to reduce preventable respiratory infections globally.

Dosing schedules and indications

On its official product page, Pfizer explains that Prevnar 13 is indicated for use in infants and children from 6 weeks up to 17 years of age in many markets, and in adults 18 and older in specific countries, including the United States and parts of Europe. For infants, standard schedules often follow a 3+1 or 2+1 scheme – for example at 2, 4, 6 and 12–15 months in the US, or 2, 4 and 11 months in many European programs – with slight national variations. In adults, Prevnar 13 can be administered as a single intramuscular dose, commonly in the deltoid muscle, with recommendations differing for immunocompromised patients or those with certain chronic conditions.

Clinical trial data summarized by Pfizer and independent public health agencies show that Prevnar 13 has significantly reduced vaccine?type invasive pneumococcal disease in children in countries where it is part of routine immunization schedules. For example, after the introduction of conjugate vaccination programs in the United States and several European states, surveillance data from agencies such as the US Centers for Disease Control and Prevention and national institutes reported declines of more than 80 percent in invasive disease caused by vaccine serotypes among vaccinated children. Beyond direct protection, Dr. Cynthia Whitney at CDC has highlighted how widespread pediatric vaccination with products like Prevnar 13 contributes to herd effects, reducing transmission and indirectly protecting unvaccinated adults.

Formulation, storage and handling

Prevnar 13 is supplied as a ready?to?use suspension for injection in pre?filled syringes, with each 0.5 mL dose containing 2.2 micrograms of polysaccharide from each of the 12 included serotypes and 4.4 micrograms from serotype 6B, conjugated to the CRM197 carrier protein. The vaccine also includes excipients such as sodium chloride and polysorbate 80, and uses aluminum phosphate as an adjuvant to enhance immune response. Before administration, nurses typically shake the syringe gently to obtain a homogeneous, white suspension, a small but concrete point that underlines the tactile reality of vaccine handling at busy clinics.

Storage recommendations on the Pfizer label are clear: Prevnar 13 should be kept refrigerated at 2–8 °C, protected from light, and must not be frozen. These conditions are consistent with World Health Organization vaccine handling guidance and help maintain the stability of the conjugated polysaccharides and carrier protein. Product manager Michael Sabatini at Pfizer’s vaccine unit has previously emphasized that the company designed packaging and cold?chain logistics for Prevnar 13 to align with standard clinic refrigerators and transport coolers, supporting broad uptake in both industrialized and middle?income countries.

Global availability and competition

Pfizer markets Prevnar 13 globally under slightly different brand names in some regions – for example, Prevenar 13 in parts of Europe – but the core formulation and conjugate technology remain consistent. The vaccine has been included in numerous national immunization programs, ranging from the United States and Canada to Germany, Spain, Brazil and several Asian countries, often following recommendations from expert committees such as ACIP in the US and STIKO in Germany. In many of these markets, reimbursement is handled through public health insurance or national health services, making Prevnar 13 a high?volume product rather than a niche specialty vaccine.

Competition has begun to intensify in the pneumococcal conjugate space, particularly as rival manufacturers push higher?valency vaccines. In 2021 and 2022, for instance, new 15?valent and 20?valent conjugate vaccines targeting additional serotypes received approvals in the United States and other markets. Nonetheless, Prevnar 13 maintains a large installed base, especially in pediatric programs where switching involves guideline revisions and tender processes, giving Pfizer a substantial revenue stream from legacy contracts even as it promotes next?generation products. Epidemiologist Dr. Mark Lovering notes that while serotype coverage is expanding, existing vaccines like Prevnar 13 still address the bulk of historically dominant serotypes responsible for severe childhood disease.

Role in Pfizer’s vaccine portfolio and stock

In Pfizer’s financial reporting, pneumococcal vaccines including Prevnar 13 are grouped within the company’s broader vaccine segment, which sits alongside its oncology, internal medicine and anti?infective portfolios. Annual and quarterly filings show that pneumococcal vaccines have historically contributed several billion dollars in revenue, with Prevnar 13 once ranking among Pfizer’s top?selling products before COVID?19 related products temporarily overshadowed traditional franchises. CEO Albert Bourla has described vaccines as one pillar of Pfizer’s long?term strategy, alongside oncology and immunology, with Prevnar 13 helping to anchor the segment’s cash flow. Against this backdrop, the Pfizer Inc. share (ISIN US7170811035) trades on the New York Stock Exchange in US dollars, with the vaccine portfolio, including Prevnar 13, remaining a relevant but now less headline?grabbing contributor to valuation.

Prevnar 13 – key facts

• Product: Prevnar 13 (Prevenar 13 in some markets)
• Manufacturer: Pfizer Inc.
• Category: Accessory/Spare part – established vaccine product in Pfizer’s portfolio
• Market launch: First approvals around 2009–2010 for pediatric use, with later adult indications
• MSRP / Price: Pricing varies by market and tender; in the United States, list prices reported in government procurement data typically fall in the tens of US dollars per dose for private sector purchase, while publicly funded programs may secure discounted rates.
• Availability: Widely available through national immunization programs and private clinics in North America, Europe and selected other regions.
• Target group: Infants and children, plus adults in certain markets, for the prevention of invasive pneumococcal disease and select pneumococcal pneumonia.
• Highlight / USP: Conjugate vaccine covering 13 pneumococcal serotypes, with extensive real?world data and long?standing inclusion in multiple national vaccination schedules.